Literature DB >> 8886428

Different subtypes of alpha 1A-adrenoceptor mediating contraction of rat epididymal vas deferens, rat hepatic portal vein and human prostate distinguished by the antagonist RS 17053.

I Marshall1, R P Burt, G M Green, M B Hussain, C R Chapple.   

Abstract

1. The alpha 1-adrenoceptor subtype mediating contraction of the rat hepatic portal vein to phenylephrine was characterized by use of competitive antagonists previously shown to have selectivity between the expressed alpha 1-subtype clones. Prazosin competitively antagonized the phenylephrine contractions with a pA2 value of 9.2, as did WB 4101 (pA2 9.4), 5-methyl urapidil (pA2 8.6), indoramin (pA2 8.4) and BMY 7378 (pA2 6.5). 2. The pA2 values on the rat portal vein correlated highly with their previously published pA2 values for the alpha 1A-adrenoceptors mediating contraction of the rat epididymal vas deferens and human prostate and poorly with those for the alpha 1B- and alpha 1D-adrenoceptors mediating contraction of the rat spleen and aorta, respectively. The antagonist pA2 values on the rat portal vein correlated highly with their previously published pK1 values for the expressed alpha 1a-clone and poorly with those for the expressed alpha 1b- and alpha 1d-clones. Therefore the results show that contraction of the rat portal vein to phenylephrine is mediated by alpha 1A-adrenoceptors. 3. The novel alpha 1-adrenoceptor antagonist RS 17053 had a relatively high affinity for the alpha 1A-adrenoceptors mediating contraction of the rat epididymal vas deferens (pA2 9.5) compared with the alpha 1B-adrenoceptors in the rat spleen (pA2 7.2) or the alpha 1D-adrenoceptors in the rat aorta (pKB 7.1), in agreement with its selectivity for the expressed alpha 1a-clone. However, RS 17053 had over 100 fold lower affinity for the alpha 1A-adrenoceptors mediating contraction of the rat portal vein (pKB 7.1) and human prostate (pKB 7.1) compared with its affinity for the alpha 1A-adrenoceptors in the rat epididymal vas deferens or the expressed alpha 1a-clone. 4. The difference in affinity of RS 17053 between the rat epididymal vas deferens and rat portal vein cannot be explained by a species difference in the receptor. Therefore RS 17053 may distinguish between subtypes of the alpha 1A-adrenoceptor in the rat portal vein and human prostate compared with those in the rat epididymal vas deferens or the expressed alpha 1a-clone.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8886428      PMCID: PMC1915842          DOI: 10.1111/j.1476-5381.1996.tb16001.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  30 in total

1.  The effect of alpha 1-acid glycoprotein on the pharmacological activity of alpha 1-adrenergic antagonists in rabbit aortic strips.

Authors:  J Chiang; G Hermodsson; S Oie
Journal:  J Pharm Pharmacol       Date:  1991-08       Impact factor: 3.765

2.  The role of alpha 1-adrenoceptor subtypes in the phasic and tonic responses to phenylephrine in the longitudinal smooth muscle of the rat portal vein.

Authors:  H R Schwietert; M A Gouw; D Wilhelm; B Wilffert; P A van Zwieten
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-05       Impact factor: 3.000

3.  alpha 1-Adrenoceptor subtype mediating contraction of the smooth muscle in the lower urinary tract and prostate of rabbits.

Authors:  K Honda; A Miyata-Osawa; T Takenaka
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-07       Impact factor: 3.000

4.  The alpha 1-adrenergic receptor that mediates smooth muscle contraction in human prostate has the pharmacological properties of the cloned human alpha 1c subtype.

Authors:  C Forray; J A Bard; J M Wetzel; G Chiu; E Shapiro; R Tang; H Lepor; P R Hartig; R L Weinshank; T A Branchek
Journal:  Mol Pharmacol       Date:  1994-04       Impact factor: 4.436

5.  Investigation of the subtypes of alpha 1-adrenoceptor mediating contractions of rat aorta, vas deferens and spleen.

Authors:  R Aboud; M Shafii; J R Docherty
Journal:  Br J Pharmacol       Date:  1993-05       Impact factor: 8.739

6.  Pharmacological properties of the cloned alpha 1A/D-adrenoceptor subtype are consistent with the alpha 1A-adrenoceptor characterized in rat cerebral cortex and vas deferens.

Authors:  B A Kenny; A M Naylor; P M Greengrass; M J Russell; S J Friend; A M Read; M G Wyllie
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

7.  Relationship between alpha-adrenoceptor occupancy and contractile response in rat vas deferens. Experimental and theoretical analysis.

Authors:  A Díaz-Toledo; M C Martí
Journal:  Eur J Pharmacol       Date:  1988-11-08       Impact factor: 4.432

8.  Identification of alpha 1-adrenoceptor subtypes in the rat vas deferens: binding and functional studies.

Authors:  T Ohmura; M Oshita; S Kigoshi; I Muramatsu
Journal:  Br J Pharmacol       Date:  1992-11       Impact factor: 8.739

9.  Pharmacological subclassification of alpha 1-adrenoceptors in vascular smooth muscle.

Authors:  I Muramatsu; T Ohmura; S Kigoshi; S Hashimoto; M Oshita
Journal:  Br J Pharmacol       Date:  1990-01       Impact factor: 8.739

10.  Activation of alpha-1A adrenoceptors mobilizes calcium from the intracellular stores in myocytes from rat portal vein.

Authors:  N Lepretre; J Mironneau; S Arnaudeau; Z Tanfin; S Harbon; G Guillon; J Ibarrondo
Journal:  J Pharmacol Exp Ther       Date:  1994-01       Impact factor: 4.030

View more
  9 in total

1.  Investigation of the subtypes of alpha1-adrenoceptor mediating contractions of rat vas deferens.

Authors:  V Honner; J R Docherty
Journal:  Br J Pharmacol       Date:  1999-11       Impact factor: 8.739

2.  Discrimination by SZL49 between contractions evoked by noradrenaline in longitudinal and circular muscle of human vas deferens.

Authors:  Nnaemeka I B Amobi; John Guillebaud; A V Kaisary; Eileen Turner; I Christopher H Smith
Journal:  Br J Pharmacol       Date:  2002-05       Impact factor: 8.739

3.  Evaluation of alpha1-adrenoceptors in the rabbit iris: pharmacological characterization and expression of mRNA.

Authors:  S Nakamura; T Taniguchi; F Suzuki; Y Akagi; I Muramatsu
Journal:  Br J Pharmacol       Date:  1999-07       Impact factor: 8.739

4.  Interaction between alpha(1)- and alpha(2)-adrenoreceptors contributes to enhanced constrictor effects of norepinephrine in mesenteric veins compared to arteries.

Authors:  Alexandra Sporkova; Alex Perez-Rivera; James J Galligan
Journal:  Eur J Pharmacol       Date:  2010-06-21       Impact factor: 4.432

5.  Analysis of alpha 1L-adrenoceptor pharmacology in rat small mesenteric artery.

Authors:  W B Stam; P H Van der Graaf; P R Saxena
Journal:  Br J Pharmacol       Date:  1999-06       Impact factor: 8.739

6.  Characterization of the alpha1-adrenoceptor subtype mediating contractions of the pig internal anal sphincter.

Authors:  Ka Mills; N Hausman; R Chess-Williams
Journal:  Br J Pharmacol       Date:  2008-06-02       Impact factor: 8.739

Review 7.  Alpha1-, alpha2- and beta-adrenoceptors in the urinary bladder, urethra and prostate.

Authors:  Martin C Michel; Wim Vrydag
Journal:  Br J Pharmacol       Date:  2006-02       Impact factor: 8.739

Review 8.  Emerging drugs to target lower urinary tract symptomatology (LUTS)/benign prostatic hyperplasia (BPH): focus on the prostate.

Authors:  Stefan Ückert; George T Kedia; Dimitrios Tsikas; Annika Simon; Andreas Bannowsky; Markus A Kuczyk
Journal:  World J Urol       Date:  2019-09-10       Impact factor: 4.226

9.  Mirabegron relaxes urethral smooth muscle by a dual mechanism involving β3 -adrenoceptor activation and α1 -adrenoceptor blockade.

Authors:  E C Alexandre; L R Kiguti; F B Calmasini; F H Silva; K P da Silva; R Ferreira; C A Ribeiro; F Z Mónica; A S Pupo; E Antunes
Journal:  Br J Pharmacol       Date:  2016-01-15       Impact factor: 8.739

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.